378 related articles for article (PubMed ID: 8402733)
41. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
[TBL] [Abstract][Full Text] [Related]
42. Human recombinant IL-4 decreases the emergence of non-specific cytolytic cells and favours the appearance of memory cells (CD4+CD45RO+) in the IL-2-driven development of cytotoxic T lymphocytes against autologous ovarian tumour cells.
Roth AD; Dupuis S; Alberto P
Clin Exp Immunol; 1995 Aug; 101(2):362-8. PubMed ID: 7648722
[TBL] [Abstract][Full Text] [Related]
43. Indomethacin modulation of adriamycin-induced effects on multiple cytolytic effector functions.
Maccubbin DL; Cohen SA; Ehrke MJ
Cancer Immunol Immunother; 1990; 31(6):373-80. PubMed ID: 2386983
[TBL] [Abstract][Full Text] [Related]
44. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
45. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
46. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
47. Effects of three irreversible inhibitors of ornithine decarboxylase on macrophage-mediated tumoricidal activity and antitumor activity in B16F1 tumor-bearing mice.
Bowlin TL; Hoeper BJ; Rosenberger AL; Davis GF; Sunkara PS
Cancer Res; 1990 Aug; 50(15):4510-4. PubMed ID: 2114941
[TBL] [Abstract][Full Text] [Related]
48. Mechanism of interferon gamma-induced protection of human gliosarcoma cells from lymphokine-activated killer lysis: division of lymphokine-activated killer cells into natural killer- and T-like cells.
Kondo S; Miyatake S; Kikuchi H; Oda Y; Iwasaki K; Ohyama K; Namba Y
Neurosurgery; 1992 Sep; 31(3):534-40. PubMed ID: 1407434
[TBL] [Abstract][Full Text] [Related]
49. Intratumoral rIL2-based immunotherapy in B16 melanoma.
Yeung RS; Vollmer C; Taylor DD; Palazzo J; Weese JL
J Surg Res; 1992 Aug; 53(2):203-10. PubMed ID: 1405610
[TBL] [Abstract][Full Text] [Related]
50. Effect of IFN-gamma treatment and in vivo passage of murine tumor cell lines on their sensitivity to lymphokine-activated killer (LAK) cell lysis in vitro; association with H-2 expression on the target cells.
Tsai L; Ohlén C; Ljunggren HG; Kärre K; Hansson M; Kiessling R
Int J Cancer; 1989 Oct; 44(4):669-74. PubMed ID: 2507452
[TBL] [Abstract][Full Text] [Related]
51. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
52. Interleukin-7 mediates the generation and expansion of murine allosensitized and antitumor CTL.
Jicha DL; Schwarz S; Mulé JJ; Rosenberg SA
Cell Immunol; 1992 Apr; 141(1):71-83. PubMed ID: 1555257
[TBL] [Abstract][Full Text] [Related]
53. Antitumor mechanism of recombinant murine interleukin-12 vaccine.
Yin X; Yan X; Yang Q; Cao H; Liang H
Cancer Biother Radiopharm; 2010 Jun; 25(3):263-8. PubMed ID: 20578831
[TBL] [Abstract][Full Text] [Related]
54. Phenotypic and functional heterogeneity of thymic and splenic lymphokine activated killer cells relative to ornithine sensitivity.
Mehrotra P; Bear HD; Susskind BM
Cell Immunol; 1991 Feb; 132(2):451-65. PubMed ID: 1899052
[TBL] [Abstract][Full Text] [Related]
55. Targeted delivery of murine IFN-gamma using a recombinant fowlpox virus: NK cell recruitment to regional lymph nodes and priming of tumor-specific host immunity.
Zeytin H; Reali E; Zaharoff DA; Rogers CJ; Schlom J; Greiner JW
J Interferon Cytokine Res; 2008 Feb; 28(2):73-87. PubMed ID: 18279103
[TBL] [Abstract][Full Text] [Related]
56. Decrease of lymphokine (interleukin-2)-activated killer activity in peripheral blood after administration of natural interferon-gamma.
Yanagawa H; Sone S; Okubo A; Fukuta K; Nishioka Y; Ogura T
Jpn J Clin Oncol; 1990 Dec; 20(4):356-63. PubMed ID: 2126575
[TBL] [Abstract][Full Text] [Related]
57. Effect of electric foot shock and psychological stress on activities of murine splenic natural killer and lymphokine-activated killer cells, cytotoxic T lymphocytes, natural killer receptors and mRNA transcripts for granzymes and perforin.
Li Q; Liang Z; Nakadai A; Kawada T
Stress; 2005 Jun; 8(2):107-16. PubMed ID: 16019602
[TBL] [Abstract][Full Text] [Related]
58. Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice.
Baxevanis CN; Voutsas IF; Tsitsilonis OE; Tsiatas ML; Gritzapis AD; Papamichail M
Eur J Immunol; 2000 Jul; 30(7):1957-66. PubMed ID: 10940885
[TBL] [Abstract][Full Text] [Related]
59. In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice.
Puri RK; Leland P
Clin Exp Immunol; 1991 Aug; 85(2):317-25. PubMed ID: 1713814
[TBL] [Abstract][Full Text] [Related]
60. Differential modulation by interferon gamma of the sensitivity of human melanoma cells to cytolytic T cell clones that recognize differentiation or progression antigens.
Kirkin AF; thor Straten P; Zeuthen J
Cancer Immunol Immunother; 1996 May; 42(4):203-12. PubMed ID: 8665567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
